Lymphocyte ratio and heart artery disease severity
Part of Heart & circulation clinical trials.
This study looks at whether the ratio of certain blood cells can predict the complexity of blocked heart arteries. It may help doctors choose the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have had a heart attack treated with a stent, or you have known heart artery disease and are scheduled for a stent procedure
- You have no prior heart attacks, previous stents, or heart bypass surgery
- You do not have an autoimmune disease, chronic inflammatory condition, active infection, or cancer
- You are not on medications that weaken the immune system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how severely blocked a coronary artery is using measurements taken during a planned heart catheterization, to help guide whether and how to do a stent (PCI). It may help doctors choose the best treatment plan for people with about 70% or more narrowing.
This study looks at real-world outcomes for people with narrowed heart arteries (coronary artery disease). It may include those treated with stents (PCI) or medicines. Doctors will use a special computer tool to measure the severity of blockages and track health over time.
This study compares two types of coronary artery disease: one linked to inflammation (IR-CAD) and the standard type (AS-CAD). If you have had a heart procedure and were recently hospitalized for worsening chest pain, this study may help doctors understand your condition better.
This trial looks at people with a blockage in a heart artery of 50% or more. It tests a new way to check the blockage using a special CT scan. This could help decide the best treatment to prevent future heart problems.
This trial compares two ways to decide which heart artery blockages need treatment: one looks at blood flow, the other at plaque buildup and risk. It's for people with high-risk blockages to see which approach leads to better outcomes.
This study looks at whether a comprehensive add-on treatment—starting with immune medicine and then a heart procedure when needed—can improve outcomes for people whose coronary artery disease is getting worse quickly. It focuses on cases where inflammation is likely driving new artery blockages or worsening chest pain.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.